First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

NCT ID: NCT04795037

Last Updated: 2022-07-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 81 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-07-15
• Study Completion Date: 2022-06-25

Brief Summary

This clinical trial is the first-in-human study of CU06-1004. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.

Conditions

Diabetic Macular Edema

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

CU06-1004 for SAD

• Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts
• 6 of out 8 subjects per cohort will be randomized to receive CU06-1004

Group Type: EXPERIMENTAL

CU06-1004, Single dose

Intervention Type: DRUG

Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)＊

＊Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5

Placebo for SAD

• Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts
• 2 of out 8 subjects per cohort will be randomized to receive placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo matched to CU06-1004, oral capsule

CU06-1004 for MAD

• Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts
• 6 of out 8 subjects per cohort will be randomized to receive CU06-1004

Group Type: EXPERIMENTAL

CU06-1004, Multiple doses

Intervention Type: DRUG

Multiple doses of CU06-1004, 7 days, 3 dose levels＊, oral capsule

＊The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD

Placebo for MAD

• Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts
• 2 of out 8 subjects per cohort will be randomized to receive placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo matched to CU06-1004, oral capsule

Interventions

CU06-1004, Single dose

Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)＊

＊Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5

Intervention Type: DRUG

CU06-1004, Multiple doses

Multiple doses of CU06-1004, 7 days, 3 dose levels＊, oral capsule

＊The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD

Intervention Type: DRUG

Placebo

Placebo matched to CU06-1004, oral capsule

Intervention Type: DRUG

Other Intervention Names

SAC-1004; CU06; CU06-RE; SAC-1004; CU06; CU06-RE

Eligibility Criteria

Inclusion Criteria

1. Healthy, adult, male or female (of non-childbearing potential only), 19-55 years of age, inclusive, at screening.

2. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at screening.

3. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study, based on subject self-reporting.

4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.

5. Female must be of non-childbearing potential and must have undergone one of the following sterilization procedures at least 6 months prior to the first dosing:

• hysteroscopic sterilization;
• bilateral tubal ligation or bilateral salpingectomy;
• hysterectomy;
• bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to the first dosing and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status.

6. A non-vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days after the last dosing.

(No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to the first dosing. A male who has been vasectomized less than 4 months prior to the first dosing must follow the same restrictions as a non-vasectomized male).

7. If male, must agree not to donate sperm from the first dosing until 90 days after the last dosing.

8. Able to swallow multiple capsules.

9. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

Exclusion Criteria

1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.

2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.

3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.

4. History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.

5. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.

6. Female subjects of childbearing potential.

7. Female subjects with a positive pregnancy test at screening or first check-in or who are lactating.

8. Positive urine drug or alcohol results at screening or first check-in.

9. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).

10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg, at screening.

11. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.

12. QTcF interval is >460 msec (males) or >470 msec (females) or has ECG findings deemed abnormal with clinical significance by the PI or designee at screening.

13. Unable to refrain from or anticipates the use of:

• Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements (especially sulforaphane-containing supplement) beginning 14 days prior to the first dosing and throughout the study. After randomization, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the PI or designee.
• Food and beverages containing xanthines/caffeine for 24 hours prior to the first dosing (small amounts of caffeine derived from normal foodstuffs e.g.,250 mL/8 oz./1 cup decaffeinated coffee or other decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz. chocolate bar, per day, would not be considered a deviation to this restriction).
• Food and beverages containing alcohol for 48 hours prior to the first dosing.
• Food and beverages containing grapefruit/Seville orange for 14 days prior to the first dosing.
• Food and beverages containing vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard) and charbroiled meats for 14 days prior to the first dosing.

14. Has received COVID-19 vaccine within 30 days of first dosing and until the end of the study.

15. Has been on a diet incompatible with the on-study diet, in the opinion of the PI or designee, within the 30 days prior to the first dosing and throughout the study.

16. Is lactose intolerant (FE cohort only).

17. Donation of blood or significant blood loss within 56 days prior to the first dosing.

18. Plasma donation within 7 days prior to the first dosing.

19. Participation in another clinical study within 30 days prior to the first dosing. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to the first dose of study drug in the current study.

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

KCRN Research, LLC

INDUSTRY

Sponsor Role: collaborator

Curacle Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ji-Hye Kang, Ph.D

Role: STUDY_DIRECTOR

Curacle Co., Ltd.

Locations

Celerion

Lincoln, Nebraska, United States

Countries

United States

References

Maganti L, Panebianco DL, Maes AL. Evaluation of methods for estimating time to steady state with examples from phase 1 studies. AAPS J. 2008;10(1):141-7. doi: 10.1208/s12248-008-9014-y. Epub 2008 Feb 28.

Reference Type: BACKGROUND

PMID: 18446514 (View on PubMed)

Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80. doi: 10.1007/BF01068419.

Reference Type: BACKGROUND

PMID: 3450848 (View on PubMed)

Other Identifiers

CU06-1004-DME-01

Identifier Type: -

Identifier Source: org_study_id